Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SFDA To Prioritize Raising Standards For Essential Drugs

This article was originally published in PharmAsia News

Executive Summary

China's State FDA will soon release regulations on tightening the monitoring and supervision of the quality of essential drugs, with a focus on raising standards for these items. SFDA officials point out that the implementation of a new national essential drugs system will boost the usage of drugs on the list, thus any slip-up could have serious consequences. The agency demands that local drug administrations should strictly enforce provisions of the upcoming regulations; fully understand the types of essential drugs when the list is released, as well as their status, supervisory objectives and measures; enhance monitoring along the entire pathway of drug R&D, production, distribution and application; and raise the level of scientific management. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072628

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel